EP 0891425 A2 19990120 - METHODS AND COMPOSITIONS FOR REGULATING T CELL SUBSETS BY MODULATING TRANSCRIPTION FACTOR ACTIVITY
Title (en)
METHODS AND COMPOSITIONS FOR REGULATING T CELL SUBSETS BY MODULATING TRANSCRIPTION FACTOR ACTIVITY
Title (de)
METHODE UND ZUSAMMENSETZUNGEN FÜR DIE REGULIERUNG VON T-ZELLUNTEREINHEITEN DURCH MODULATION DER AKTIVITÄT VON TRANSKRIPTIONSFAKTOREN
Title (fr)
PROCEDES ET COMPOSITIONS POUR LA REGULATION DE SOUS-ENSEMBLES DE LYMPHOCYTES T PAR LA MODULATION DE L'ACTIVITE DU FACTEUR DE TRANSCRIPTION
Publication
Application
Priority
- US 9706708 W 19970423
- US 63660296 A 19960423
- US 75558496 A 19961125
- US 75559296 A 19961125
Abstract (en)
[origin: WO9739721A2] Methods for modulating production of a T helper type 2 (Th2)-associated cytokine, in particular interleukin-4, by modulating the activity of one or more transcription factors that cooperate with NF-AT family proteins to regulate expression of a Th2-associated cytokine gene are disclosed. In one embodiment, the activity of a maf family protein (e.g., c-Maf or a small maf protein, such as p18) is modulated. In another embodiment, the activity of a protein that interacts with an NF-AT family protein (e.g., NIP45) is modulated. Combination methods, for example wherein the activities of a maf family protein and an NF-AT protein are modulated or the activities of a maf protein and an NF-AT-interacting protein are modulated, are also encompassed by the invention. Methods for modulating development of T helper type 1 (Th1) or T helper type 2 (Th2) subsets in a subject using agents that modulate transcription factor activity are also disclosed. NIP45 compositions, including isolated nucleic acid molecules encoding NIP45, antisense nucleic acid molecules, recombinant expression vectors containing a NIP45 nucleic acid molecule, host cells into which such expression vectors have been introduced and non-human transgenic animals carrying a NIP45 transgene, are also provided by the invention. The invention further provides isolated NIP45 proteins and peptides, NIP45 fusion proteins and anti-NIP45 antibodies. Methods of using the NIP45 compositions of the invention are also disclosed.
IPC 1-7
C12N 15/12; C12N 15/10; C07K 16/18; C12N 15/62; A01K 67/027; G01N 33/68; C12N 15/63; C07K 14/47
IPC 8 full level
A01K 67/027 (2006.01); A61K 31/00 (2006.01); A61K 31/70 (2006.01); A61K 38/00 (2006.01); A61K 39/395 (2006.01); A61K 39/44 (2006.01); A61K 45/06 (2006.01); A61K 48/00 (2006.01); A61P 35/00 (2006.01); A61P 37/00 (2006.01); C07K 14/47 (2006.01); C07K 14/52 (2006.01); C07K 14/54 (2006.01); C07K 14/82 (2006.01); C07K 16/18 (2006.01); C07K 19/00 (2006.01); C12N 5/10 (2006.01); C12N 15/09 (2006.01); C12N 15/12 (2006.01); C12N 15/62 (2006.01); C12N 15/63 (2006.01); C12P 21/08 (2006.01); G01N 33/15 (2006.01); G01N 33/50 (2006.01); G01N 33/53 (2006.01); G01N 33/68 (2006.01)
CPC (source: EP KR)
A01K 67/027 (2013.01 - KR); A61P 35/00 (2017.12 - EP); A61P 37/00 (2017.12 - EP); C07K 14/47 (2013.01 - KR); C07K 14/4702 (2013.01 - EP); C07K 14/52 (2013.01 - EP); C07K 14/5406 (2013.01 - EP); C07K 14/82 (2013.01 - EP); C07K 16/18 (2013.01 - KR); C12N 5/10 (2013.01 - KR); C12N 15/11 (2013.01 - KR); C12N 15/62 (2013.01 - KR); C12N 15/63 (2013.01 - KR); G01N 33/68 (2013.01 - KR); A01K 2217/05 (2013.01 - EP); A61K 38/00 (2013.01 - EP); C07K 2319/00 (2013.01 - EP)
Citation (search report)
See references of WO 9739721A2
Designated contracting state (EPC)
AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
DOCDB simple family (publication)
WO 9739721 A2 19971030; WO 9739721 A3 19980409; AU 3115597 A 19971112; AU 720455 B2 20000601; CA 2252643 A1 19971030; CN 1225682 A 19990811; EP 0891425 A2 19990120; JP 2000510333 A 20000815; KR 20000010606 A 20000215; NZ 332897 A 20000428
DOCDB simple family (application)
US 9706708 W 19970423; AU 3115597 A 19970423; CA 2252643 A 19970423; CN 97195740 A 19970423; EP 97926377 A 19970423; JP 53827897 A 19970423; KR 19980708492 A 19981023; NZ 33289797 A 19970423